In the last trading session, 1.06 million Adaptive Biotechnologies Corp (NASDAQ:ADPT) shares changed hands as the company’s beta touched 1.48. With the company’s per share price at $6.30 changed hands at -$0.23 or -3.52% during last session, the market valuation stood at $929.75M. ADPT’s last price was a discount, traded about -6.35% off its 52-week high of $6.70. The share price had its 52-week low at $2.28, which suggests the last value was 63.81% up since then. When we look at Adaptive Biotechnologies Corp’s average trading volume, we note the 10-day average is 1.79 million shares, with the 3-month average coming to 1.17 million.
Analysts gave the Adaptive Biotechnologies Corp (ADPT) stock a consensus recommendation rating of Hold, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 1 out of 11 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 6 recommended ADPT as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adaptive Biotechnologies Corp (NASDAQ:ADPT) trade information
Instantly ADPT was in red as seen at the end of in last trading. With action 12.90%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 28.57%, with the 5-day performance at 12.90% in the green. However, in the 30-day time frame, Adaptive Biotechnologies Corp (NASDAQ:ADPT) is 18.64% up. Looking at the short shares, we see there were 8.2 million shares sold at short interest cover period of 7.86 days.
The consensus price target for the stock as assigned by Wall Street analysts is 14, meaning bulls need an upside of 55.0% from its current market value. According to analyst projections, ADPT’s forecast low is 5 with 18 as the target high. To hit the forecast high, the stock’s price needs a -185.71% plunge from its current level, while the stock would need to tank 20.63% for it to hit the projected low.
Adaptive Biotechnologies Corp (ADPT) estimates and forecasts
Data shows that the Adaptive Biotechnologies Corp share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 85.84% over the past 6 months, a 18.84% in annual growth rate that is considerably higher than the industry average of 17.60%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -32.91%. The 2024 estimates are for Adaptive Biotechnologies Corp earnings to increase by 28.53%.
ADPT Dividends
Adaptive Biotechnologies Corp is expected to release its next quarterly earnings report in January.
Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.93% of Adaptive Biotechnologies Corp shares while 93.97% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 95.81%. There are 93.97% institutions holding the Adaptive Biotechnologies Corp stock share, with VIKING GLOBAL INVESTORS LP the top institutional holder. As of 2024-06-30, the company held 20.5736% of the shares, roughly 29.99 million ADPT shares worth $108.58 million.
RUBRIC CAPITAL MANAGEMENT LP holds the second largest percentage of outstanding shares, with 9.603% or 14.0 million shares worth $50.68 million as of 2024-06-30.
